]>
IRCT20160118026097N3 IRCT 2020-05-31 Ghoum University of Medical Sciences The effect of interferon on the treatment of covid19 patients ندارد Evaluation of interferon treatment in high-risk covid19 patients in Qom 2020-03-20 anticipated 60 Complete https://irct.ir/trial/48517 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: no, Randomization description: Randomization through block allocation. 3 COVID19. Intervention 1: Intervention group: In addition to receiving treatment protocol from the Ministry of Health, after obtaining informed consent, it will be treated with interferon. Intervention 2: Control group: They are treated only by the protocol of the Ministry of Health. Yes - There is a plan to make this available What will be shared: All potential data can be shared after people have not been identified When: Start the access period 6 months after printing the results To whom: It will be available for researchers working in academic and scientific institutions Conditions: According to the rules of the COPE Where to obtain: jvafaeemanesh@yahoo.com How to obtain: Email the responsible author Comments: no
public jamsheed vafaeemanesh
beheshti blvd
qom Iran (Islamic Republic of) 3719964797 +98 25 3612 2526 jvafaeemanesh@yahoo.com Ghoum University of Medical Sciences scientific jamshid vfaeemanesh
beheshti blvd
qom Iran (Islamic Republic of) 3719964797 +98 25 3612 2526 jvafaeemanesh@yahoo.com Ghoum University of Medical Sciences Iran (Islamic Republic of) Laboratory confirmation of Covid19 infection with reverse transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source A new organ dysfunction related to Covid19 Being an adult 18 years 70 years Both Intention to commit suicide (interfering with interferon (IFN) -b1b). Sensitivity or sensitivity reaction to Lupinavir / Ritonavir or IFN-β1b recombinant, including toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome. ALT above 5 times normal Use of drugs that are contraindicated with lopinavir / ritonavir and should not be substituted or discontinued during the study period, such as CYP3A inhibitors. pregnancy.Eligible female participants are tested at gestational age before enrolling in the study for pregnancy. HIV Vulnerable groups Treatment - Drugs Treatment - Drugs Intervention group: In addition to receiving treatment protocol from the Ministry of Health, after obtaining informed consent, it will be treated with interferon. Control group: They are treated only by the protocol of the Ministry of Health Death within 30 days of hospitalization. Timepoint: every day. Method of measurement: View. Days without organ support (for example, supplemental O2, mechanical ventilation, dialysis and vasopressors). Timepoint: Time interval: 28 days. Method of measurement: View. Results of RT-PCR in lower respiratory samples. Timepoint: Time interval: At the time of entering the study and one week after treatment and repetition every week until the negative sample of the period. Method of measurement: test. Body Failure Assessment Scores (SOFA). Timepoint: Time frame: days 1, 3, 5, 7, 14 and 28). Method of measurement: check list. Ghoum University of Medical Sciences Approved 2020-04-28 Ethics committee of qom University of Medical Sciences qom qom Ghoum Iran (Islamic Republic of)